Hanmi Pharm. Co., Ltd.
128940.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.09T
Close$
$287983.50
25.4% downside
Current Fair Value
25.4% downsideOvervalued by 25.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.09 Trillion |
|---|---|
| Enterprise Value | $6.34 Trillion |
| Dividend Yield | $2250.00 (0.42%) |
| Earnings per Share | $13371 |
| Beta | 0.49 |
| Outstanding Shares | 12,930,000 |
Return
| Return on Equity | 15.46% |
|---|---|
| Return on Assets | 9.30% |
| Return on Invested Capital | 16.49% |
Valuation & Multiples
| P/E Ratio | 25.95 |
|---|---|
| PEG | 22.51 |
| Price to Sales | 3.01 |
| Price to Book Ratio | 3.14 |
| Enterprise Value to Revenue | 3.83 |
| Enterprise Value to EBIT | 22.64 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.33 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 28, 2026
EPS Estimate
$4062.00
Average shareholder expectationRevenue Estimate
$468.96 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$3207.00
Average shareholder expectationRevenue Estimate
$453.36 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hanmi Pharm. Co., Ltd.
2,270 employees
CEO: Jae-Hyun Park A globally active pharmaceutical company, Hanmi Pharm. Co., Ltd. was established in Seoul, South Korea, in 1973. The firm concentrates its efforts on researching and developing medical therapies for a range of health issues, including di...